Trial Profile
A phase 2 double-blind, randomized, placebo-controlled, parallel group study of the pharmacodynamic effects of orally administered 100microg and 1000microg QD MD-1100 acetate on gastrointestinal transit in patients with constipation predominant irritable bowel syndrome (C-IBS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Linaclotide (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 27 Oct 2006 Status change
- 23 Aug 2006 New trial record.